Live Breaking News & Updates on துறை ஆஃப் சோதனை மருந்து
Stay updated with breaking news from துறை ஆஃப் சோதனை மருந்து. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate announcements from Olink Proteomics AB, Announcing Olink Signature Q100: facilitating access for researchers to Olink technology with a benchtop system dedicated to multiplex protein biomarker measurement ....
GeNeuro: Researchers Detect HERV-W ENV in COVID-19 Patients and Link Expression to Disease Severity Data published in the Lancet s EBioMedicine shows that the pathogenic envelope protein of the human endogenous retrovirus W (HERV-W ENV) is found on lymphocytes of hospitalized patients with COVID-19, and that its level of expression is associated with disease severity. HERV-W ENV s pro-inflammatory properties thought to act as an accelerant of the activation of the innate immune system, fueling the severity of COVID-19 evolution and impacting long term recovery. Preliminary data available on Research Square also shows HERV-W ENV expression in lymphocytes following in vitro exposure to SARS-CoV-2 in about 20% of healthy blood donors, suggesting individual susceptibility. ....
Share this article WOODCLIFF LAKE, N.J., Jan. 20, 2021 /PRNewswire/ Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Dr. Richard Woodman as Chief Clinical Officer (CCLO) of its Oncology Business Group. In this role, Dr. Woodman will have full oversight and responsibility for the strategic and operational leadership of the company s global oncology clinical development functions, including clinical research, clinical operations, imaging, medical writing, data services, biostatistics and regulatory strategy. He will also serve as a member of the Oncology Executive Leadership team. Dr. Richard Woodman Dr. Woodman, who has 18 years of pharmaceutical experience in several different functional areas at both large and small biotech organizations, will lead the clinical team s development of Eisai s next generation oncology products by managing the design protocols and implementation of all oncology clinic ....